These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18724617)

  • 21. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
    Dufour JF; Hoppe H; Heim MH; Helbling B; Maurhofer O; Szucs-Farkas Z; Kickuth R; Borner M; Candinas D; Saar B
    Oncologist; 2010; 15(11):1198-204. PubMed ID: 21036880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Multimodality treatment for hepatocellular carcinoma].
    Malek NP; Vogel A; Manns MP
    Internist (Berl); 2010 Nov; 51(11):1374-81. PubMed ID: 20938626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Diagnosis and treatment of hepatocellular carcinoma].
    Forner A; Ayuso C; Isabel Real M; Sastre J; Robles R; Sangro B; Varela M; de la Mata M; Buti M; Martí-Bonmatí L; Bru C; Tabernero J; Llovet JM; Bruix J
    Med Clin (Barc); 2009 Feb; 132(7):272-87. PubMed ID: 19248879
    [No Abstract]   [Full Text] [Related]  

  • 24. 18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma.
    Siemerink EJ; Mulder NH; Brouwers AH; Hospers GA
    Oncologist; 2008 Jun; 13(6):734-5; author reply 736-7. PubMed ID: 18586929
    [No Abstract]   [Full Text] [Related]  

  • 25. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
    Herden U; Fischer L; Schäfer H; Nashan B; von Baehr V; Sterneck M
    Transplantation; 2010 Jul; 90(1):98-9. PubMed ID: 20606568
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
    Li Y; Huang JW; Lu LG; Shao PJ; Hu BS; Huang GM; Wei ZG; Zhang L
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(31):2187-92. PubMed ID: 21029658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treating hepatocellular carcinoma without liver transplantation.
    Gogia S; Befeler AS
    Curr Gastroenterol Rep; 2009 Feb; 11(1):69-75. PubMed ID: 19166662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
    Kim R; Menon N; Aucejo F
    Med Oncol; 2011 Dec; 28(4):1044-7. PubMed ID: 20635167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
    Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
    Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The emerging questionable benefit of sorafenib as a neo-adjuvant in HCC patients treated with Y-90 radioembolization pending liver transplantation.
    Shouval D
    J Hepatol; 2014 Aug; 61(2):190-2. PubMed ID: 24845608
    [No Abstract]   [Full Text] [Related]  

  • 31. Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
    Kim DY; Han KH
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1585-6. PubMed ID: 22011294
    [No Abstract]   [Full Text] [Related]  

  • 32. Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.
    Chan SL; Johnson P
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):111-4. PubMed ID: 22524569
    [No Abstract]   [Full Text] [Related]  

  • 33. Sorafenib for liver cancer: the horizon broadens.
    Johnson P; Billingham L
    Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
    [No Abstract]   [Full Text] [Related]  

  • 34. Sorafenib in advanced hepatocellular carcinoma.
    Palmer DH
    N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
    [No Abstract]   [Full Text] [Related]  

  • 35. Interventional therapies for hepatocellular carcinoma.
    Willatt JM; Francis IR; Novelli PM; Vellody R; Pandya A; Krishnamurthy VN
    Cancer Imaging; 2012 Apr; 12(1):79-88. PubMed ID: 22487698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
    Hua XD; He ZY
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):790-2. PubMed ID: 23291076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocellular carcinoma: the search for innovative adjuvant therapies.
    Yen Y; Zhou W
    Oncology (Williston Park); 2009 Dec; 23(14):1291, 1294. PubMed ID: 20120843
    [No Abstract]   [Full Text] [Related]  

  • 38. Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
    Verset G; Maréchal R; Bali MA; Devière J; Van Laethem JL
    Ann Oncol; 2010 Jun; 21(6):1381-1382. PubMed ID: 20332137
    [No Abstract]   [Full Text] [Related]  

  • 39. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatocellular carcinoma: epidemic and treatment.
    Allen J; Venook A
    Curr Oncol Rep; 2004 May; 6(3):177-83. PubMed ID: 15066228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.